Anesiva is to file for bankruptcy protection after its proposed merger with Arcion Therapeutics, which appeared to be the struggling pharmaceutical company's saviour in August, was terminated.
Anesiva is to file for bankruptcy protection after its proposed merger with Arcion Therapeutics, which appeared to be the struggling pharmaceutical company's saviour in August, was terminated.
Anesiva announced on December 31st that it had failed to satisfy the closing conditions of the deal, which required it...
Sumitomo Pharma's iPSC therapy for Parkinson's has been filed for approval in Japan after showing safety and efficacy in a Phase I/II trial and may become one of the first such therapies to reach the market in the country, which has invested heavily in the modality.
A Phase II trial to develop a second NaV1.8 pain signal inhibitor for acute pain has failed and the US FDA has given a thumbs down on Journavx’s path to broader use in peripheral neuropathic pain.
AbbVie now expects the two Humira successors to bring in $25bn this year. On its Q2 earnings call, the firm also pointed to strength in neuroscience, with 24% growth.
Sales of Leqembi, Zurzuvae and Skyclarys contributed to Biogen’s sales and earnings guidance raise, positioning the company closer to potential growth.
